Splotch mice, which harbour mutations in the Pax3 gene, exhibit neural crest-related abnormalities including pigmentation defects, reduced or absent dorsal root ganglia and failure of cardiac outflow tract septation in homozygotes. Although splotch neural crest cells fail to colonise target tissues, they initiate migration in vivo and appear to migrate as well as wild type neural crest cells in vitro, suggesting that the neural crest abnormality in splotch may reside not in the neural crest cells themselves, but rather in the extracellular environment through which they migrate. We have examined the expression of genes encoding extracellular matrix molecules in Sp 2H homozygous embryos and find a marked over-expression of transcripts for the chondroitin sulphate proteoglycan versican in the pathways of neural crest cell migration. Use of cadherin-6 expression as a marker for neural crest demonstrates a striking correlation between up-regulation of versican expression and absence of migrating neural crest cells, both in the mesenchyme lateral to the neural tube and in the lower branchial arches of Sp 2H homozygotes. Pax3 and versican have mutually exclusive expression patterns in normal embryos whereas, in Sp 2H homozygotes, versican is generally over-expressed with 'infilling' in regions that would normally express functional Pax3. Versican, like other chondroitin sulphate proteoglycans, is non-permissive for migration of neural crest cells in vitro, and we suggest that over-expression of this molecule leads to the arrest of neural crest cell migration in splotch embryos. Pax3 may serve to negatively regulate versican expression during normal development, thereby guiding neural crest cells into their pathways of migration.
Introduction
The neural crest arises from the dorsal part of the vertebrate neural tube, and migrates over large distances to participate in the development of various organ systems (Horstadius, 1950; Weston, 1970; Le Douarin, 1982) . Although it is well known that neural crest cells (NCC) follow specific routes towards their target locations (Erickson, 1988; Serbedzija et al., 1990 Serbedzija et al., , 1994 , the mechanisms by which these routes are specified is less well understood. For instance, both NCC and extending motor axons prefer to migrate through the rostral part of the somite rather than the caudal part, whereas other tissues, including the dermomyotome and the perinotochordal mesenchyme, act as barriers to NCC migration (Keynes and Stern, 1984; Newgreen et al., 1986; Pettway et al., 1996) .
There is growing evidence that particular extracellular matrix molecules can be either permissive or inhibitory to NCC migration. Permissive molecules tend to be expressed along migration routes whereas inhibitory molecules are localised in regions avoided by neural crest. For instance, fibronectin, tenascin and laminin-heparan sulphate proteoglycan complexes are supportive of NCC migration in vitro, and their expression in vivo is suggestive of a role in promoting migration towards target tissues (Newgreen and Thiery, 1980; Krotoski et al., 1986) . On the other hand, molecules including the chondroitin sulphate proteoglycans versican and collagen IX, T-cadherin, and the Eph-ligands Lerk2 and HtkL are found in barrier tissues such as the caudal sclerotome and the perinotochordal mesenchyme, and have been suggested to limit NCC migration and motor axon outgrowth (Perris and Johansson, 1987; Tan et al., 1987; Ranscht and Bronner-Fraser, 1991; Landolt et al., 1995; Ring et al., 1996; Wang and Anderson, 1997) .
One way to further analyse the molecular mechanisms of NCC migration is to determine the underlying defect in mutant systems where migration of the neural crest fails. Splotch mice, in which there are mutations of the Pax3 transcription factor (Epstein et al., 1991) , are well known genetic models of NCC migration defects. Homozygotes for several of the splotch alleles, including Sp and Sp
2H
, manifest neural crest-related abnormalities including reduced or absent dorsal root ganglia, Schwann cell deficiency and persistent truncus arteriosus. Homozygotes also exhibit neural tube defects and lack limb musculature (Chalepakis et al., 1993) . Although the limb muscle defects have been studied in some detail (Bober et al., 1994; Goulding et al., 1994) , few workers have examined the mechanisms underlying NCC abnormalities in splotch mice.
Recently, we showed that the congenital heart defect persistent truncus arteriosus develops in Sp 2H homozygotes as a result of the failure of the cardiac neural crest to populate the outflow tract of the heart (Conway et al., 1997a,b) . The cardiac neural crest arises from the occipital neural tube at E9.5 and migrates through the lower branchial arches en route to the cardiac outflow tract. We found that the cardiac neural crest can be recognised by virtue of its expression of genes including Pax3, Hoxa3, Crabp1, Prx1, Prx2 and cmet. In homozygous Sp 2H embryos, the cardiac neural crest appears to initiate migration, as cells can clearly be seen exiting from the hindbrain at approximately E9.5 (Conway et al., 1997a) . Moreover, NCC cultures can readily be established in vitro from the neural tubes of both wild type and splotch mutant embryos (Moase and Trasler, 1990; Drossopoulou, Conway, Henderson and Copp, unpublished) . Recently, it was shown that splotch NCC are capable of migrating through host tissues following grafting into the chick embryo (Serbedzija and McMahon, 1997) . Taken together, these findings indicate that splotch NCC are intrinsically capable of normal migration, but may be prevented from reaching their target locations by inhibitory interactions with their migratory environment. Indeed, abnormalities in the extracellular matrix of splotch embryos have been described previously: in particular, the expression of chondroitin sulphate-containing proteoglycans appears enhanced (Trasler and Morriss-Kay, 1991) . This prompted the present study, in which we compared the expression of the gene encoding the chondroitin sulphate proteoglycan versican in wild type and homozygous Sp 2H embryos at the time of NCC migration.
Versican is a member of a family of aggregating chondroitin sulphate proteoglycans (Zimmermann and Ruoslahti, 1989 ) that also includes aggrecan (Doege et al., 1987) and two proteoglycans expressed in the brain, brevican and neurocan (Rauch et al., 1992; Yamada et al., 1994) . Using in situ hybridisation, we find marked over-expression of versican in the pathways of neural crest migration in homozygous Sp 2H embryos. Migrating NCC can be recognised by virtue of their expression of cadherin-6 which is highly specific for the neural crest at this stage of development (Inoue et al., 1997) . Use of this marker demonstrates a close regional correlation between over-expression of versican and absence of migrating NCC. These findings suggest that Pax3 may normally act to regulate versican expression and that this regulatory interaction is disrupted in splotch leading to inhibition of NCC migration by a nonpermissive extracellular environment.
Results
In order to examine mouse embryos for the expression of versican mRNA, we used RT-PCR to amplify two regions of the coding sequence ( Fig. 1) corresponding to the V 1 and V 2 splice variants of versican (Ito et al., 1995) . In preliminary experiments, both probes yielded identical patterns by in situ hybridisation, so the V 1 probe was used for the remainder of the study.
Versican is expressed in mouse embryonic tissues avoided by migrating neural crest
Versican is expressed in the wild type embryo throughout the developmental period studied, from E9 to E12.5. This is in agreement with data from antibody staining of the versican core protein in the chick (Landolt et al., 1995) . At E9.5 we found versican transcripts in the developing somites, neural tube and hindgut (Fig. 2 ). Expression appears most intense in the rostral somites whereas more caudal somites have lower transcript levels ( Fig. 2A) . At the most caudal levels of the body, versican mRNA is expressed throughout the presomitic mesoderm (Fig. 2D ). In the neural tube, versican expression also exhibits cranio-caudal variation: at upper spinal levels, versican is largely excluded from the neural tube (Fig. 2B) whereas, in the caudal region, there is marked expression of versican throughout the neuroepithelium (Fig. 2D) . Similarly, the developing hindgut is positive for versican at E9.5 (Fig. 2D ) whereas the foregut is negative (Fig. 2B) .
Versican expression in the somites becomes refined as development proceeds and by E10.5 transcripts are found principally in the caudal part of each somite (Fig. 3A,F) which is known to be avoided by the migrating NCC. At this stage, versican is seen at highest levels in the mesoderm dorsolateral to the developing dorsal root ganglia and ventro-medial to the dermomyotome (Fig. 3B,D) . Strikingly, no expression is seen in the dermomyotome itself, nor in the dorsal root ganglia. Versican is also expressed in the sclerotome adjacent to and surrounding the notochord. At the level of the fore limb buds, versican is expressed strongly in a domain immediately lateral to the dermomyotome where the dorsal surface of the limb is continuous with the flank. At E11.5, expression of versican continues in the caudal part of each somite with transcript levels still highest in the dorsal mesoderm adjacent to the neural tube and lateral to the dorsal root ganglia (Fig. 4 A,B) . The latter do not express versican mRNA. By this stage, versican is becoming down-regulated in the sclerotome and around the notochord (Fig. 4B) . The domain of versican expression at the dorsal margin of the forelimb bud remains clearly demarcated, whereas the more medially situated dermomyotome entirely lacks versican transcripts (Fig. 4B) .
At later stages of gestation, versican expression decreases in the mesoderm lateral to the neural tube and becomes elevated in condensing cartilage (data not shown), as previously described for the chick (Landolt et al., 1995) .
Versican is over-expressed in paraxial mesoderm of Sp 2H embryos in association with defective NCC migration
We compared the pattern and intensity of expression of versican mRNA in wild type and homozygous Sp 2H embryos between E9.5 and E11.5 (Figs. 2-4) . The distribution of migrating neural crest was also evaluated in closely stage-matched embryos at E9.5 using the neural crest marker cadherin-6 (Fig. 5) , which is highly specific for NCC at this stage of development (Inoue et al., 1997) . Versican mRNA is markedly over-expressed in Sp 2H /Sp 2H embryos compared with wild type littermates at E9.5, with the most pronounced difference observed in the rostral somites and in the mesoderm lateral to the hindbrain ( Fig. 2A-C) . In sections through this region in wild type embryos, a stream of cells, negative for versican, can be seen migrating through the positively expressing somite (Fig. 2B ). These cells express cadherin-6, in contrast to the surrounding mesoderm, which is negative, identifying the migrating cells as neural crest (Fig. 5B) . In contrast, Sp 2H /Sp 2H embryos exhibit vastly increased levels of versican transcripts throughout the paraxial mesoderm at this level of the body axis, with no evidence of migrating versican-negative cells (Fig. 2C) . Indeed, use of the cadherin-6 marker confirms that migrating NCC are absent from the paraxial mesoderm of homozygous Sp 2H embryos (Fig. 5C) . A localised clump of cadherin-6 positive cells is visible just lateral to the neural tube in mutant embryos (Fig. 5C ), where versican transcripts are absent (Fig. 2C) , consistent with the idea that mutant NCC can emigrate from the neural tube, but are unable to migrate through the versican-rich paraxial mesoderm. We conclude that neural crest can migrate through an environment comprising cells expressing low levels of versican, whereas excessive versican expression is associated with failure of NCC migration in the homozygous Sp 2H embryo.
Defective NCC migration through the lower branchial arches is associated with over-expression of versican in Sp 2H homozygotes
We also detected marked over-expression of versican in the region of the developing branchial arches 4 and 6 in Sp 2H /Sp 2H embryos ( Fig. 2A , black arrows). Arch 1 also exhibits marginally more versican transcripts in mutant than wild type embryos, whereas expression in arches 2 and 3 appears closely similar in mutant and wild type embryos ( Fig. 2A) This finding correlates well with the expression of cadherin-6-positive NCC through the branchial arches which is similar in wild type and mutant embryos for arches 1 and 2 at E9.5 ( Fig. 5A ) and for arch 3 at E10.5 (data not shown). In contrast, there is a complete lack of migration through the developing arches 4 and 6, and more caudally, in Sp 2H homozygotes at both E9.5 ( Fig. 5A ) and E10.5 (data not shown). In contrast, wild type embryos exhibit plentiful NCC migration at the level of arches 4 and 6, and at more caudal levels (Fig. 5A ). Moreover, it seems likely that the NCC traversing arches 4 and 6 include the cardiac neural crest, since cadherin-6-positive cells are present in the immediate vicinity of the aortic sac, just superior to the cardiac outflow tract in wild type embryos (Fig. 5D ), whereas these cells are entirely absent from Sp 2H homozygotes (Fig. 5E ). Thus, the over-expression of versican is restricted to post-otic regions of splotch embryos and these regions are specifically associated with defective NCC migration.
Over-expression of versican in Sp 2H embryos at later stages of gestation
Homozygous Sp 2H embryos also over-express versican at E10.5, in particular within the occipital and cervical regions (Fig. 3A) . Sections of the whole-mount embryos reveal ectopic expression of versican in dorsal mesoderm adjacent to the neural tube, and in dorsal sclerotome, between the neural tube and the dermomyotome. Versican expression extends into the region where dorsal root ganglia are forming in wild type embryos (Fig. 3B,C) . In contrast, there is no apparent over-expression in the ventral sclerotome of (5), lectin-like (6) and complement regulatory protein-like (7) domains are shared between the splice variants. Probe A detects the V 1 variant which bears the b chondroitin sulphate attachment domain (4), whereas probe B detects the V 2 variant which carries the a domain (3). The V 0 full length unspliced transcript is detected by both probes. Non-coding regions of the transcripts are designated by thin lines. The information for this diagram is taken from Ito et al. (1995 (Fig.  4) . The expression pattern of versican increasingly reflects the mutant morphological phenotype so that, in embryos with a large spina bifida, there is often ectopic expression of versican in the area occupied by the dermomyotome, resulting in an enlarged domain of expression extending uninterrupted from the dorsal-most mesoderm to the hindlimb bud (Fig. 4A,C) . In embryos with a large exencephaly, a similar phenomenon occurs at the level of the forelimb bud (data not shown). Elsewhere in the embryo, for instance within the limb buds, the expression of versican is remarkably similar between mutant and wild type embryos.
At E12.5, the expression pattern of versican is becoming more similar between wild type and Sp 2H /Sp 2H embryos although there is still abnormal expression of versican in the somites, with the separation of expression domains in adjacent somites appearing less distinct in Sp 2H /Sp 2H embryos than in wild type littermates (data not shown).
Patterns of versican and Pax3 expression are reciprocal during normal development
In view of the abnormal pattern of versican expression in the Pax3 mutant Sp 2H , we examined in detail the relationship between Pax3 and versican expression in normal embryos. Sections of hybridised embryos reveal a reciprocal expression of Pax3 and versican in the paraxial mesoderm (Figs. 6 and 7) . Wherever Pax3 is expressed versican is completely excluded and, conversely, wherever versican is expressed Pax3 is absent. This reciprocal expression pattern gradually emerges as development proceeds: at early E9, Pax3 and versican are co-expressed in the condensing somitic mesoderm although expression levels are low at this stage (data not shown). By E9.5, Pax3 has become restricted to the developing dermomyotome and is down-regulated in the sclerotome, whereas, versican expression is maintained in the sclerotome and in the dorsal mesoderm immediately adjacent to the neural tube, but is down-regulated in the developing dermomyotome (data not shown).
By E10.5 and E11.5, expression patterns of Pax3 and versican are strikingly reciprocal (Figs. 6 and 7). Pax3 is expressed in wild type embryos in the dorsal neural tube, the dermomyotome, in muscle progenitor cells migrating into the limb bud and, with lower intensity, in the recently emerged NCC (Fig. 6A ) and the dorsal-most part of the dorsal root ganglia (Fig. 7A) . Versican is excluded from the dermomyotome but is expressed strongly in the mesoderm dorso-medial to the dermomyotome, and in the sclerotome and perinotochordal mesoderm, where there is no Pax3 expression (Figs. 6B and 7B). Versican expression is also intense in the dorsal part of the limb bud where it extends from the flank, a region that corresponds precisely with a gap in Pax3 expression between the lateral end of the dermomyotome and the myotomal cells of the limb (Figs. 6B and 7B, arrowheads). (Fig. 6C ) although the protein product is predicted to lack much of the C-terminal region, and may be largely absent from the mutant embryo (Henderson and Copp, unpublished) . Thus the expectation is that versican would be ectopically expressed in Sp 2H /Sp 2H embryos, wherever Pax3 is expressed in wild type embryos. Indeed, versican expression appears to 'infill' in regions such as the dermomyotome, the mesoderm lateral to the dorsal part of the neural tube and the site of the dorsal root ganglia (Fig. 6D) . On the other hand, there is no upregulation of versican in the dorsal neural tube, suggesting that any negative regulatory control of versican by Pax3 is tissue-specific, encompassing the mesoderm but not the neuroepithelium. At E11.5, in the Sp 2H mutant embryo the expression of Pax3 appears truncated in the dermomyotome and there is 'infilling' of versican expression in the mutant where Pax3 would normally be expressed (Fig. 7C,D) . 
Versican expression 'infills' in regions of

Abnormal expression of versican in Sp 2H embryos is a specific effect
We asked whether the abnormal expression of versican in the paraxial mesoderm of Sp 2H /Sp 2H embryos is a specific effect or whether it reflects a generalised abnormality of gene expression in the paraxial mesoderm. To resolve this question, the expression of several other mesodermally expressed genes was examined in Sp 2H /Sp 2H and wild type embryos. Pax1 is a mesodermal marker that is expressed throughout the sclerotome from the time of its formation. Examination of Pax1 by whole-mount in situ hybridisation at E9.5-11.5 revealed no major differences in expression between Sp 2H homozygotes and wild type littermates (Fig.  8) . In addition, other proteoglycans were examined to determine whether there is a generalised over-abundance of the extracellular matrix in the Sp 2H embryo. Examination of both perlecan and aggrecan (data not shown) showed no obvious abnormalities between mutant and wild type embryos.
We conclude that versican, a molecule inhibitory to neural crest migration, is specifically over-expressed and transcribed in ectopic sites in Sp 2H /Sp 2H mutant embryos during the development of NCC migration defects. Furthermore, versican and Pax3 exhibit reciprocal expression patterns such that they are expressed in mutually exclusive domains within the caudal part of the somite. These data suggest that versican is regulated by Pax3 during normal development of the mesoderm and that the NCC migration defects seen in Sp 2H homozygotes may be explained, at least in part, by the failure of the mutated Pax3 to correctly downregulate versican in the pathways of NCC migration.
Discussion
Splotch homozygous embryos have a variety of neural crest-related defects that could be related to mutations in Pax3 in one of two ways. Pax3 expression in NCC might be a prerequisite for their migration, so that mutant NCC lose their ability to migrate, or Pax3 mutations could have an indirect effect, making the extracellular environment inhospitable for NCC migration. Several pieces of evidence support the second of these hypotheses. NCC are clearly able to migrate in the cranial region of splotch embryos, as craniofacial defects rarely form part of the mutant phenotype. Indeed, Auerbach (1954) drew attention to the cranio-caudal gradient of increasing severity of neural crest-related defects along the embryonic axis in splotch, and we have demonstrated relatively normal migration of cadherin-6-positive NCC through the rostral branchial arches. At occipital/cervical and more caudal levels of the body axis, although NCC emerge from the neural tube at E9.5, they are absent from the lower branchial arches of Sp 2H /Sp 2H embryos at E10.5 (Conway et al., 1997a) . On the other hand, NCC isolated from hindbrain and trunk of splotch and wild type embryos are able to migrate similarly on plastic and fibronectin-coated substrates for periods of up to 72 h (Moase and Trasler, 1990; Drossopoulou, Conway, Henderson and Copp, unpublished) . Moreover, grafting fragments of splotch neural tube into chick embryos demonstrates that splotch NCC are capable of migrating through host tissues (Serbedzija and McMahon, 1997) . These data support the idea that the neural crest of splotch mutants is intrinsically capable of normal migration and suggest that the extracellular environment may inhibit its migration at post-otic levels in vivo.
Versican as a candidate for suppression of NCC migration in Sp 2H
We have demonstrated that the gene encoding the chondroitin sulphate proteoglycan versican is expressed in tissues that provide a barrier to NCC migration, therefore confirming the observations made in chick embryos using an anti-versican antibody (Landolt et al., 1995) . Moreover, we find that versican is over-expressed in homozygous Sp 2H embryos within dorsal paraxial mesoderm, between the neural tube and the surface ectoderm. Over-expression is detected before NCC begin their emigration from the neural tube, demonstrating that the versican defect is very unlikely to be secondary to the abnormality of NCC migration. Using cadherin-6 as a marker of migrating neural crest (Inoue et al., 1997) , we find that NCC emigrate from the Sp 2H /Sp 2H neural tube but remain as a localised clump of cells immediately adjacent to the neural tube, whereas wild type NCC can be observed as a stream of migrating cells within the paraxial mesoderm. These findings suggest that NCC migration is inhibited in Sp 2H homozygous embryos almost as soon as the cells leave the neural tube and that they are unable to migrate through the versican-rich paraxial mesoderm.
Versican is also over-expressed in Sp 2H homozygotes in mesoderm situated both medial and lateral to the dermomyotome, sites that are normally occupied by migrating neural crest. Moreover, we observed increased abundance of versican transcripts in the lower branchial arches, through which NCC are known to migrate towards the out- ; n = 6) embryos by whole-mount in situ hybridisation. (A) Wild type (left) and Sp 2H /Sp 2H (right) embryos exhibit closely similar expression of cadherin-6 in branchial arches 1 and 2, and in the ventral forebrain (f) region, indicating that neural crest migration is relatively normal at these sites in mutant embryos. In contrast, cadherin-6-positive cells can be observed migrating through developing arches 4 and 6, and at more caudal levels in the wild type embryo, whereas these cells are almost entirely absent from the mutant embryo. /Sp 2H (C,E) embryos. The dorsal opening of the neural tube in these embryos is a fixation artefact. Cadherin-6-positive NCC can be seen migrating through the paraxial mesoderm of the wild type embryo (arrowheads in (B)) in a pattern that corresponds closely to the stream of versican-negative cells shown in Fig. 2B . The homozygous Sp 2H embryo does not exhibit this stream of cadherin-6-positive cells. Instead, a clump of cells expressing cadherin-6 is visible lateral to the dorsal region of the neural tube (arrows in (C)) indicating that NCC emigrate from the mutant neural tube but do not migrate through the versican-rich paraxial mesoderm. Sections at a slightly more rostral level demonstrate abundant cadherin-6-positive cells surrounding the wild type aortic sac (ao) just superior to the outflow tract (arrowheads in (D)) whereas these cells are absent from the mutant embryo (arrows in (E)). Abbreviations: a, atrium; ba, first branchial arch; bp, second branchial pouch; v, ventricle. Scale bar, (A) 0.5 mm; (B,C) 160 mm. flow tract of the heart. Use of the cadherin-6 marker demonstrates that NCC are beginning to traverse the developing arches 4 and 6 in E9.5 wild type embryos, and are migrating into the vicinity of the outflow tract, whereas these cells are absent from Sp 2H homozygotes. On the other hand, both mutant and wild type embryos exhibit NCC migrating through arches 1, 2 and 3, and this correlates with a closely similar level of versican expression in these branchial arches.
Direct evidence of the ability of versican to inhibit NCC migration has come from in vitro studies in which substrates coated with versican, and the related proteoglycan aggrecan, fail to promote attachment and outgrowth of neural crest, in contrast to fibronectin which is permissive for outgrowth (Perris et al., 1996) . Moreover, chondroitin sulphate proteoglycans, possibly including versican, are also implicated in the lethal spotting mouse mutant, where an inhospitable extracellular environment inhibits neural crest colonisation of the terminal bowel, resulting in aganglionic megacolon (Tennyson et al., 1990) . We conclude, therefore, that over-expression of versican may well be responsible for the failure of NCC migration in the splotch mutant.
Versican is unlikely to mediate the defect of migratory muscle progenitors in Sp
2H
Splotch mutants have abnormalities of the limb and body wall musculature, involving defective migration of myoblast progenitors from the dermomyotome (Bober et al., 1994; Goulding et al., 1994) . The ventral part of the dermomyotome in splotch embryos fails to express either Pax3 or c-met and it has been proposed that the absence of c-met expression is responsible for the failure of dermomyotomal migration (Daston et al., 1996; Yang et al., 1996) . Versican (C,D) embryos at E10.5 following whole-mount in situ hybridisation. Pax3 is expressed in wild type embryos in the dorsal part of the neural tube, the dermomyotome and in muscle progenitor cells migrating into the limb. Low level expression is also seen in NCC just after emigration from the neural tube. In mutant embryos, truncated Pax3 transcripts are present in a similar distribution in the dorsal neural tube whereas expression is diminished in the dermomyotome and absent from the paraxial mesoderm and limb buds, owing to the absence of NCC and muscle progenitors, respectively. Versican expression is strikingly reciprocal to Pax3 in wild type embryos (compare (B) with (A)), as exemplified by its expression in the dorsal mesoderm and dorsal limb bud mesoderm (arrowheads in (B)), both sites that are negative for Pax3. In Sp 2H /Sp 2H embryos, on the other hand, there is 'infilling' by versican expression in regions normally expressing Pax3 (arrows in (D)), suggesting that versican is repressed by the wild type but not mutant forms of Pax3. Abbreviations: c, early migrating neural crest cells; d, dermomyotome; g, dorsal root ganglia; m, muscle progenitor cells; n, neural tube; s, sclerotome. Scale bar, 160 mm.
might also function to guide dermomyotomal cells into the limb during normal development with disruption of this function in Sp 2H embryos. We think this is unlikely, however, since versican appears to be expressed at relatively normal levels in the limb buds of E10.5 and E11.5 embryos. Moreover, we find that embryo-to-embryo variation in the level and site of over-expression of versican correlates with variations in the severity of the NCC and neural tube defects, whereas the relatively invariant nature of the limb muscle phenotype in splotch embryos (Franz et al., 1993) is not suggestive of a causal relationship to versican overexpression. Thus, the neural crest and limb muscle aspects of the splotch phenotype may result from different cellular requirements for the Pax3 transcription factor.
Versican may negatively regulate Pax3 expression during normal development
Pax3 and versican are expressed in mutually exclusive domains within the caudal part of the somite of wild type embryos. For instance, Pax3 is expressed in the dermomyotome whereas versican appears specifically excluded from this tissue. On the other hand, examination of Sp 2H mutant embryos, shows that versican has an extended expression domain with 'infilling' in the tissues where Pax3 would normally be expressed. These findings are consistent with the idea that the normal Pax3 transcription factor negatively regulates expression of versican mRNA, and that loss of Pax3 function in the Sp 2H mutant leads to de-repression of versican, resulting in its over-expression.
Pax3 encodes a transcription factor that binds in a sequence-specific manner to the regulatory regions of other genes (Goulding et al., 1991) . A number of genes have been suggested as potential downstream targets of Pax3, including N-CAM, N-cadherin, c-met, MyoD and Myf-5 (Chalepakis et al., 1994; Edelman and Jones, 1995; Daston et al., 1996; Maroto et al., 1997; Tajbakhsh et al., 1997) . Our data suggest versican as a further target of Pax3 regulation and, moreover, support the idea that splotch mutations cause a loss of function of the Pax3 protein, even when a truncated version is potentially present, as in Sp
2H
. The direct in vivo targets of Pax3 have not yet been determined, so the specific recognition sequence for DNA binding by Pax3 is currently unknown. There is evidence, however, that Pax3 functions to negatively regulate target genes when expressed at high level (Chalepakis et al., 1994), supporting a role for Pax3 in negatively regulating versican expression, either directly or indirectly.
Role of non-permissive extracellular matrix molecules in neural crest migration
We find that versican expression in the mouse embryo is broadly similar to that in the chick (Landolt et al., 1995) , but with some important differences. For instance, versican is expressed more dorsally in the somites of the mouse, whereas versican immunoreactivity is concentrated in the sclerotome of the chick. This suggests that versican may act as a guidance cue to NCC at an earlier stage of their migration in mouse than in chick. In the perinotochordal region, another chondroitin sulphate proteoglycan may be primarily responsible for inhibition of NCC migration. Aggrecan is strongly expressed at this site in the chick (Domowicz et al., 1995) and was recently demonstrated to exist in at least two variants: early-expressed and late-expressed forms . The early form bears an HNK-1 carbohydrate epitope and is repulsive to NCC migration, whereas the later-expressed form lacks HNK-1 immunoreactivity and is not inhibitory to NCC migration . Post-transcriptional modification appears to be responsible for these functional variants of aggrecan and, perhaps for the differing inhibitory effects of versican and aggrecan on NCC migration. Aggrecan has a significantly greater inhibitory effect on NCC migration on a fibronectin substrate in vitro than versican, and this functional difference has been related to the fact that versican carries many chondroitin-6-sulphate chains whereas aggrecan carries predominantly keratan sulphate side chains, and relatively fewer chondroitin sulphates (Perris et al., 1996) .
Our findings, taken together with the results of Perris et al. (1996) , suggest that the difference in strength of inhibition of NCC attachment and migration by aggrecan and versican may have important functional effects in vivo. Aggrecan, with its strong inhibitory effect, may completely prevent the migration of NCC through regions rich in this proteoglycan, as seen in the peri-notochordal region which is avoided by NCC (Pettway et al., 1990 . On the other hand, the weaker inhibitory effect of versican means that low levels of this proteoglycan, in combination with permissive molecules such as fibronectin and laminin, are compatible with neural crest migration. The balance between permissive and non-permissive molecules appears critical in determining whether NCC can migrate: for instance, over-adhesion to substrate molecules slows the rate of migration of NCC in vitro (Perris, 1997) . In the Sp 2H mutant, we suggest that excessive expression of versican tips the balance towards a non-permissive extracellular environment, and migration is inhibited.
In conclusion, we have shown that versican is expressed, at the mRNA level, in tissues that provide a barrier to NCC migration in the mouse, and that versican is over-expressed in the routes of NCC migration in the Sp 2H /Sp 2H mutant embryo. It seems possible that the Pax3 gene may modulate the expression of versican during normal development, thereby contributing to the guidance of NCC in their pathways of migration.
Experimental procedures
Mouse strains and embryos
Sp
2H is a radiation-induced allele at the splotch locus that arose on the C3H/101 background (Beechey and Searle, 1986) . A heterozygous Sp 2H /+ female, obtained from the MRC Radiobiology Unit, Harwell, UK, was mated with a CBA/Ca male and the offspring were mated inter se to find a randomly bred colony. Sp 2H heterozygotes, identified by the presence of a white belly spot, were mated overnight to provide Sp 2H /Sp 2H homozygotes. Midday on the day of finding a copulation plug was designated 0.5 days of gestation (E0.5). Pregnant females were killed by cervical dislocation and the embryos placed in Dulbecco's modified Eagle's medium (DMEM; Gibco, UK) containing 10% fetal calf serum. The yolk sac and amnion were opened and the umbilical cord cut. The yolk sac was processed for PCR genotyping using Pax3 primers as previously described (Epstein et al., 1991) . Embryos were either immersed in 4% paraformaldehyde in phosphate buffered saline (PBS) and stored at 4°C overnight for whole-mount in situ hybridisation, or frozen at −20°C for later use in reverse transcriptase-polymerase chain reaction (RT-PCR).
Generation of cDNA probes by RT-PCR
Total RNA was isolated from E10.5 CBA/Ca embryos using Tri reagent (Molecular Research Center). RNA (1 mg) was used in the reverse transcriptase reaction according to the methodology of Kawasaki (1990) using random hexanucleotides (Gibco BRL). Primers were designed to amplify portions of either the V 1 or V 2 splice forms of mouse versican (Fig. 1) . Amplification between base pairs 6919-6939 and 7337-7357 of the V 1 transcript generated probe A and between base pairs 1469-1489 and 2009-2029 of the V 2 transcript generated probe B (Fig. 1) . Both probes were expected to detect the full length unspliced V 0 transcript (Ito et al., 1995) . Thirty cycles of amplification were carried out and fragments of the predicted size were synthesised. These fragments were ligated into the pGEM-T vector (Promega) and sequenced to confirm their identity. Probes were prepared in a similar manner for the mouse aggrecan gene using primers corresponding to base pairs 303-326 and 633-657 of the cDNA sequence and for cadherin-6 using primers corresponding to base pairs 1544-1563 and 1984-2004 of the cDNA sequence (GenBank accession number D82029). Probes for Pax1, Pax3 and perlecan were kindly supplied by Kenji Imai (Munich), Peter Grüss (Göttingen) and Douglas Noonan (Genoa), respectively.
Whole-mount in situ hybridisation
The methodology of Wilkinson (1992) was used. In brief, proteinase K-treated embryos were hybridised at 70°C overnight, washed at high stringency, and then incubated with anti-digoxigenin antibody (Boehringer-Mannheim). Incubation in the presence of 0.34 mg/ml nitroblue-tetrazolium chloride and 0.18 mg/ml 5-bromo-4-chloro-3-indolylphosphate (Gibco BRL) allowed detection of hybridised probe. The reaction was stopped and the embryos were stored at 4°C for several days to allow background to fade, before they were photographed using a Zeiss SV11 stereomicroscope, or processed for sectioning. In all cases sense controls were performed with no evidence of nonspecific hybridisation.
Vibratome sectioning of whole-mount embryos
Embryos were placed in a mixture of 0.45% gelatine, 27% albumen, 18% glucose in PBS which was solidified by addition of 1/10 volume of 30% glutaraldehyde. Embryos were sectioned at 50 mm using a Vibratome Series 1000, and sections were stored under coverslips in PBT: glycerol (1:1) at 4°C and photographed using an Axiophot (Zeiss) photomicroscope.
